Search

Your search keyword '"Volker Schellenberger"' showing total 178 results

Search Constraints

Start Over You searched for: "Volker Schellenberger" Remove constraint "Volker Schellenberger"
178 results on '"Volker Schellenberger"'

Search Results

1. Profile of Volker Schellenberger President of Amunix

2. Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors

Catalog

Books, media, physical & digital resources

3. 613 HER2-XPAT, a novel protease-activatable prodrug T cell engager (TCE), with potent T-cell activation and efficacy in solid tumors and large predicted safety margins in non-human primate (NHP)

4. A homogeneous high-DAR antibody–drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides

5. XPAT® proteins, conditionally activated T-cell engagers engineered to mitigate on-target, off-tumor toxicity for immunotherapy of solid tumors

6. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice

8. Abstract P193: AMX-818, a novel prodrug HER2-XPAT T-cell engager (TCE) with potent T cell activation, proteolytic cleavage and efficacy in xenograft tumors, and wide safety margins in NHP (Non Human Primate)

9. A homogeneous high-DAR antibody-drug conjugate platform combining THIOMABTM antibodies and XTEN polypeptides

10. Generation of Large Libraries of Random Mutants in Bacillus subtilis by PCR-Based Plasmid Multimerization

12. Abstract 1824: HER2-XPAT, a novel protease-activatable T-cell engager (TCE) with potent T-cell activation and efficacy in solid tumors and large safety margins in non-human primate (NHP)

13. GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model.

14. Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose.

15. Abstract PS17-11: Her2-xpat, a novel protease-activatable prodrug t-cell engager (tce), exhibits potent t-cell activation and efficacy in her2 tumors, yielding large predicted safety margins based on non-human primate (nhp)

16. Abstract 3376: HER2-XPAT and EGFR-XPAT: Pro-drug T-cell engagers (TCEs) engineered to address on-target, off-tumor toxicity with potent efficacy in vitro and in vivo and large safety margins in NHP

17. Insulin-XTEN® Exhibits a Size-Dependent Alteration in Tissue Action in Rats

18. Multivalent Antiviral XTEN–Peptide Conjugates with Long in Vivo Half-Life and Enhanced Solubility

19. A Novel Long-Acting Human Growth Hormone Fusion Protein (VRS-317): Enhanced In Vivo Potency and Half-Life

20. Towards a ligand targeted enzyme prodrug therapy: Single round panning of a β-lactamase scaffold library on human cancer cells

21. Extension of in vivo half-life of biologically active molecules by XTEN protein polymers

22. Characterization of a CC49-Based Single-Chain Fragment−β-Lactamase Fusion Protein for Antibody-Directed Enzyme Prodrug Therapy (ADEPT)

23. Construction and optimization of a CC49-Based scFv-β-lactamase fusion protein for ADEPT

24. Rapid Evolution of Novel Traits in Microorganisms

25. Rapid in vivo evolution of a β-lactamase using phagemids

26. Selection of a subtilisin-hyperproducing Bacillus in a highly structured environment

27. Extension of in vivo half-life of biologically active peptides via chemical conjugation to XTEN protein polymer

28. Evaluation of Recombinant Fixfc-Xten Bleeding Efficacy in Hemophilia-B Mouse Models

29. Substrate preferences of Vsr DNA mismatch endonuclease and their consequences for the evolution of the Escherichia coli K-12 genome

30. GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model

31. Role of the S' Subsites in Serine Protease Catalysis. Active-Site Mapping of Rat Chymotrypsin, Rat Trypsin, .alpha.-Lytic Protease, and Cercarial Protease from Schistosoma mansoni

32. Analysis of enzyme specificity by multiple substrate kinetics

33. ChemInform Abstract: Protease-Catalyzed Kinetically Controlled Peptide Synthesis

34. How to predict product yield in kinetically controlled enzymatic peptide synthesis

35. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner

36. Proteasekatalysierte kinetisch kontrollierte Peptidsynthese

37. Protease-Catalyzed Kinetically Controlled Peptide Synthesis

38. Electrostatic effects in the α-chymotrypsin-catalyzed acyl transfer. II. Efficiency of nucleophiles bearing charged groups in various locations

39. Salt-Enhanced Aminolysis of Acyl-α-Chymotrypsins by Dipeptides

40. Identification of Active Coagulation Factor IX Variants with Insertion or Fusion of Unstructured Polypeptide Xten

41. Prolonged Half-Life and Improved Recovery of Recombinant Factor IX-XTEN Fusion Proteins in Hemophilia B Mouse Model

42. Recombinant FVIIIFc-VWF-XTEN Demonstrates Significant Bioavailability Following Subcutaneous Administration in Hemophilia A Mice

43. Platelet-Targeted rFVIIa-Xten Improves Thrombin Generation and Fibrin Formation Compared to Recombinant FVIIa

44. Evaluation of Enhanced in Vitro Plasma Stability of a Novel Long Acting Recombinant FVIIIFc-VWF-XTEN Fusion Protein

45. A beta-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy

48. Penicillin acylase-catalyzed protection and deprotection of amino groups as a promising approach in enzymatic peptide synthesis

49. Characterization of the S′-subsite specificity of V8 proteinase via acyl transfer to added nucleophiles